gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LXRXHealthcarePharmaceuticals

Lexicon Pharmaceuticals, Inc. (LXRX)

$1.48+1.37%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$1.46▲ 7.35% in range
Nov 3, 2025Low $1.14 · High $2.64Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Lexicon Pharmaceuticals closed at $1.48 on Nov 4, up 1.37%, 43.9% below its 52-week closing high. Volume of 2.0M shares was 1.04× its 20-day average (close to normal).

Split-adjusted performance: -15.4% over one month, -7.5% over six months, +8.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $692K, down 97.6% from a year earlier, with a net margin of -4591.8%.

Short interest was 26.7M shares at the Oct 15 settlement, up 3.4% from the prior report (11.8% of float, 13.0 days to cover).

Market cap$658.5M445.0M shares
Revenue · quarter$692.0K−97.6% YoY
Diluted EPS$-0.07−800.0% YoY
P/E · TTM—P/S 15.9×
Net margin-4,591.8%Gross 94.4%
Dividend yieldNone
52-week range1.14 – 2.64−43.9% from high
Volume2.0M1.04× 20-day avg
Volatility · 60d51.9%Annualised
Short % of float11.8%13.0 days to cover
Net cash$139.2MCash $190.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.3%1M −15.4%3M −37.3%6M −7.5%YTD +28.7%1Y +8.8%3Y +23.3%5Y −71.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum67
Revenue growth10
Net margin9
Value (low P/E)—
Size64

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short26.7M+3.4% vs prior
Days to cover13.0Settled Oct 15
% of float11.8%
Short vol. 10d61.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LXRXLexicon Pharmaceuticals$1.48+1.37%−7.5%−97.6%−4591.8%—$658.5M
OLMAOlema Pharmaceuticals$7.54+2.58%−50.4%———$659.7MCompare
IMMXImmix Biopharma$7.97+3.37%−22.8%———$660.7MCompare
ZVRAZevra Therapeutics$11.17+8.87%−0.7%+44.9%48.8%8.6$663.3MCompare
AVBPArriVent BioPharma$13.49+3.61%−54.5%———$665.2MCompare
DSGNDesign Therapeutics$10.63+2.80%−26.9%———$665.2MCompare
KURAKura Oncology$7.61−22.98%−20.4%+36.5%−327.3%—$677.0MCompare
OBXObsidian Therapeutics$10.99−16.93%————$678.9MCompare
APMDApnimed$15.30+1.59%————$637.0MCompare

News about Lexicon Pharmaceuticals

All news →
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% TodayThe Motley Fool · Sep 28, 2026▲ PositiveLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsGlobeNewswire Inc. · Jun 3, 2026▲ PositiveNavigating Life with Hypertrophic CardiomyopathyGlobeNewswire Inc. · May 14, 2026▲ PositiveLexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingGlobeNewswire Inc. · Apr 17, 2026▲ Positive

Quick answers

What does Lexicon Pharmaceuticals do?
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases.
What is LXRX's market cap?
$658.53M, based on the Nov 4 close of $1.48.
Does Lexicon Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LXRX is sold short?
26.7M shares, 11.8% of float, as of Oct 15, 2026.
What sector is LXRX in?
Healthcare, in the Pharmaceuticals industry.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

HQ: The Woodlands, TX81 employeesListed Apr 7, 2000lexpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology